10 Results for "

RNA methyltransferase activity

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "RNA methyltransferase activity" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-156677
CAS No.: 2648257-56-9
Purity:  99.90%
Target:  

METTL3

Research Areas:  

Cancer

STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-162080
CAS No.: 374705-10-9
Research Areas:  

Cancer

METTL1-WDR4-IN-1 (Compound 1) is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC50 = 144 μM). METTL1-WDR4-IN-1 inhibits the m 7G methyltransferase activity of the METTL1-WDR4 complex, blocking m 7G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8 + T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0086R
CAS No.: 1867-73-8
Synonyms: 6-Methyladenosine (Standard); N-Methyladenosine (Standard)
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-162080A
Research Areas:  

Cancer

METTL1-WDR4-IN-1 (Compound 1) TFA is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC50=144 μM). METTL1-WDR4-IN-1 TFA inhibits the m 7G methyltransferase activity of the METTL1-WDR4 complex, blocking the m 7G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 TFA can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8 + T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 TFA can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy .
loading...
    loading...
Cat. No.: HY-108986
CAS No.: 96969-83-4
Purity:  99.40%
Target:  

Sirtuin SARS-CoV

Research Areas:  

Cancer

JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .
loading...
    loading...
Cat. No.: HY-176701
CAS No.: 3025838-18-7
Research Areas:  

Cancer

PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC50=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-175228
Target:  

RNA MTase Bacterial

Research Areas:  

Infection

RNA MTase-IN-1 (Compound 47) is a RNA methyltransferase (RNA MTase) inhibitor with an IC50 of 68  μM for 16S rRNA (m 1A1408) methyltransferase (NpmA). RNA MTase-IN-1 has a significant inhibitory activity against pathogen-associated aminoglycoside-resistance. RNA MTase-IN-1 can be used for resistant bacterial infections research .
loading...
    loading...
Cat. No.: HY-108986R
CAS No.: 96969-83-4
Research Areas:  

Cancer

JFD00244 (Standard) is the analytical standard of JFD00244 (HY-108986). This product is intended for research and analytical applications. JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .
loading...
    loading...
Cat. No.: HY-181064
Research Areas:  

Cancer

FWG-33B is an activator of TRMT112:METTL5 complex with an IC50 value of 0.47 μM. FWG-33B can be used for the research of breast carcinoma, hepatocellular carcinoma, nasopharyngeal carcinoma .
loading...
    loading...
Cat. No.: HY-184263
CAS No.: 1309199-66-3
Target:  

DNA/RNA Synthesis CHIKV

Research Areas:  

Infection

CHVB-032 is an antiviral agent and SFV nsP1 inhibitor. CHVB-032 inhibits the methyltransferase and guanylyltransferase activities of nsP1, blocks viral RNA capping process, and suppresses post-entry steps in CHIKV replication. CHVB-032 inhibits CHIKV replication across different isolates, but shows no activity against other alphaviruses. CHVB-032 can be used in research related to chikungunya fever and CHIKV infection .
loading...
    loading...